BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, has announced the extension of the system's CE Mark.Recently covered on our pages with news of promising one year study data, Revivent is a less invasive ventricular...
Emboline™, Inc., developer of total embolic protection technology for transcatheter aortic valve...read the full article >
Approvals / Clearance
Boston Scientific Corporation has announced the CE Mark approval of its Vercise™ Neural...read the full article >
Clinical Studies / Trials
Abbott has announced the launch of the TRILUMINATE Pivotal trial to evaluate the safety and...read the full article >
Orchestra BioMed™, Inc., tells us it has received CE Mark approval for its...read the full article >